In recent years, leveraging the immune system to treat cancer by inhibiting immune checkpoints such as CTLA4, PD-1, and PD-L1 has resulted in a significant breakthrough in the field of cancer treatment [58,59,60]. This evidence concerns the gene CTLA4 and cancer.